SANOFI (SNW.DE) Stock Price & Overview

FRA:SNWFR0000120578

Current stock price

80.18 EUR
-0.27 (-0.34%)
Last:

The current stock price of SNW.DE is 80.18 EUR. Today SNW.DE is down by -0.34%. In the past month the price increased by 5.39%. In the past year, price decreased by -10.55%.

SNW.DE Key Statistics

52-Week Range74.92 - 98.27
Current SNW.DE stock price positioned within its 52-week range.
1-Month Range75.48 - 83.55
Current SNW.DE stock price positioned within its 1-month range.
Market Cap
97.193B
P/E
10.25
Fwd P/E
9.36
EPS (TTM)
7.82
Dividend Yield
5.09%

SNW.DE Stock Performance

Today
-0.34%
1 Week
-3.21%
1 Month
+5.39%
3 Months
-5.02%
Longer-term
6 Months -3.83%
1 Year -10.55%
2 Years -13.88%
3 Years -19.93%
5 Years -8.33%
10 Years N/A

SNW.DE Stock Chart

SANOFI / SNW Daily stock chart

SNW.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to SNW.DE. When comparing the yearly performance of all stocks, SNW.DE is a bad performer in the overall market: 83.64% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SNW.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to SNW.DE. Both the profitability and the financial health of SNW.DE get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SNW.DE Earnings

On January 29, 2026 SNW.DE reported an EPS of 1.53 and a revenue of 11.30B. The company beat EPS expectations (4.58% surprise) and missed revenue expectations (-2.08% surprise).

Next Earnings DateApr 23, 2026
Last Earnings DateJan 29, 2026
PeriodQ4 / 2025
EPS Reported€1.53
Revenue Reported11.303B
EPS Surprise 4.58%
Revenue Surprise -2.08%

SNW.DE Forecast & Estimates

30 analysts have analysed SNW.DE and the average price target is 97.77 EUR. This implies a price increase of 21.94% is expected in the next year compared to the current price of 80.18.

For the next year, analysts expect an EPS growth of 9.55% and a revenue growth 7.45% for SNW.DE


Analysts
Analysts76
Price Target97.77 (21.94%)
EPS Next Y9.55%
Revenue Next Year7.45%

SNW.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

SNW.DE Financial Highlights

Over the last trailing twelve months SNW.DE reported a non-GAAP Earnings per Share(EPS) of 7.82. The EPS increased by 1.82% compared to the year before.


Income Statements
Revenue(TTM)70.49B
Net Income(TTM)12.49B
Industry RankSector Rank
PM (TTM) 17.71%
ROA 9.85%
ROE 17.49%
Debt/Equity 0.22
Chartmill High Growth Momentum
EPS Q2Q%16.79%
Sales Q2Q%7%
EPS 1Y (TTM)1.82%
Revenue 1Y (TTM)5.29%

SNW.DE Ownership

Ownership
Inst Owners46.54%
Shares1.21B
Float1.08B
Ins Owners0.02%
Short Float %N/A
Short RatioN/A

About SNW.DE

Company Profile

SNW logo image Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

IPO: 2002-07-01

SANOFI

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE FR

Employees: 74846

SNW Company Website

SNW Investor Relations

Phone: 33153774000

SANOFI / SNW.DE FAQ

Can you describe the business of SANOFI?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.


What is the current price of SNW stock?

The current stock price of SNW.DE is 80.18 EUR. The price decreased by -0.34% in the last trading session.


Does SNW stock pay dividends?

SANOFI (SNW.DE) has a dividend yield of 5.09%. The yearly dividend amount is currently 3.79.


What is the ChartMill rating of SANOFI stock?

SNW.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is SANOFI (SNW.DE) stock traded?

SNW.DE stock is listed on the Frankfurt Stock Exchange exchange.


What is the GICS sector and industry of SNW stock?

SANOFI (SNW.DE) operates in the Health Care sector and the Pharmaceuticals industry.